On 9 March 2020, Beroni Group Limited (OTCQX: BNIGF; NSX: BTG), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that its development of a medical solution using nanobody technology for the novel coronavirus (COVID-19) in collaboration with Tianjin University in China has advanced into cytological experiments in March 2020.
The research team has been able to obtain the information on the coronavirus nanobody sequence and the complex crystal structure of SARS-CoV-2, the virus causing the infection. The joint scientific teams have already studied the biochemical characterization of the modified nanobody. After evaluating the effect of the antibody modification, the teams are now moving into cytological experiments, which are expected to be completed this month. Shortly thereafter, we will conduct animal experiments followed by clinical trials, which are expected to occur in April 2020.
Concurrently, Beroni is in discussions with an international CRO/CDMO company with operations in the USA, Europe and China to use their research and manufacturing facilities to accelerate the clinical trials for both the diagnostic kit and medical treatment.
The full announcement can be found at https://www.nsx.com.au/ftp/news/021737911.PDF. This news is also highlighted in several online media sites, as follows:
Contract Pharma
BioWorld
https://www.bioworld.com/articles/433573-other-news-to-note-for-march-9-2020
BioSpace
BioPortfolio
Genetic Engineering & Biotechnology News
Reuters
